4DMedical Ltd.

As of June 30, 2025, 4DMedical Ltd. carries a market capitalization of 111.73M, placing it among publicly traded companies globally. Its enterprise value stands at 109.16M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

4DMedical Ltd.'s next confirmed earnings release is scheduled for February 26, 2027.

As of June 30, 2025, 4DMedical Ltd. has 465.54M shares outstanding.

These figures are as of June 30, 2025. The price-to-sales ratio is 8.92, and the price-to-book ratio stands at 1.74.

These figures are as of June 30, 2025. The EV/Sales ratio of 18.89 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 109.16M versus a market cap of 111.73M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2025, 4DMedical Ltd. maintains a current ratio of 0.89, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 6.71, indicating elevated leverage, while an interest coverage ratio of -4,879.85 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2025, 4DMedical Ltd. posted a negative return on equity (ROE) of -44.49, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -27.77, reflecting losses generated across the asset base. The company generates approximately 46,600.01 in revenue per employee across its workforce of 124.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.32 indicates how many times 4DMedical Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2025, 4DMedical Ltd. recorded an income tax benefit of -87,118.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -30.16M and -30.07M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, 4DMedical Ltd.'s stock has gained approximately 103.78% over the past 52 weeks. The 50-day moving average sits at 3.83, while the 200-day moving average is 4.11.

Over the twelve months ended June 30, 2025, 4DMedical Ltd. generated 5.78M in revenue and converted that into -30.07M in net income, yielding earnings per share of -0.14. EBITDA reached -42.24M, while operating income came in at -47.57M.

As of June 30, 2025, 4DMedical Ltd. holds 6.88M in cash and equivalents against 4.31M in total debt, resulting in a net debt position of -6.88M. Total book value stands at 64.24M, with working capital of -2.19M providing operational flexibility.

These figures cover the twelve months ended June 30, 2025.

Over the twelve months ended June 30, 2025, 4DMedical Ltd. posted a gross margin of 91.96, reflecting its pricing power and cost economics. The operating margin of -823.32 and net profit margin of -520.38 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2025. Total shareholder yield is negative at -11.07, meaning 4DMedical Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2025, 4DMedical Ltd. has an Altman Z-Score of -14.44, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.